How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular

Alberico L Catapano1, Magdalena Daccord2, Elaine Damato3

  • 1Director Center for the Study of Atherosclerosis at Bassini Hospital University of Milan, Milan, Italy.

Atherosclerosis
|March 16, 2022
PubMed

Insights

Wider measurement of Lipoprotein (a) [Lp(a)], a key inherited risk factor for atherosclerotic cardiovascular disease (ASCVD), offers significant clinical and economic benefits today. Addressing barriers to Lp(a) testing is crucial for realizing these advantages.

Area of Science:

  • Cardiology
  • Clinical Chemistry
  • Health Economics

Background:

  • Elevated Lipoprotein (a) [Lp(a)] is an inherited, causal risk factor for atherosclerotic cardiovascular disease (ASCVD).
  • Understanding the clinical utility and economic impact of widespread Lp(a) measurement is essential for cardiovascular disease (CVD) management.
  • Current guidelines and awareness may limit the broader adoption of Lp(a) testing.

Purpose of the Study:

  • To investigate the clinical utility of measuring Lipoprotein (a) [Lp(a)] concentrations for patients.
  • To evaluate the economic benefits to healthcare systems and society of wider Lp(a) measurement.
  • To identify barriers to Lp(a) measurement uptake and propose solutions.

Main Methods:

  • A structured literature review was conducted to identify economic and health benefits and costs associated with Lp(a) measurement.
  • Potential barriers to Lp(a) testing uptake and solutions were identified.
  • Findings were discussed in an advisory board with experts and patient organizations.

Main Results:

  • Wider measurement of Lp(a) concentration provides clinical and economic benefits to patients, healthcare systems, and society, even before specific Lp(a)-lowering treatments are available.
  • Increased Lp(a) measurement uptake can support the development of crucial epidemiological data.
  • The study identified key barriers including perceived limited clinical value, lack of awareness, insufficient data on CV benefit, and technical/guideline/healthcare system issues.

Conclusions:

  • Addressing barriers such as perceived limited clinical value and lack of awareness is vital for increasing Lp(a) measurement uptake.
  • Collaboration between scientific communities and industry is needed to overcome technical and guideline challenges.
  • Policy interventions are crucial for national atherosclerotic cardiovascular disease (ASCVD) plans to recognize the importance of Lp(a) testing.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
113
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
56
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
163
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
90
Lifestyle Factors and Health01:20

Lifestyle Factors and Health

Lifestyle factors play a critical role in maintaining overall health and preventing chronic diseases. Key elements, such as regular physical activity, a nutritious diet, and abstinence from smoking, can significantly enhance physical, mental, and emotional well-being while reducing the risk of several life-threatening conditions.
Benefits of Physical Activity
Physical activity, whether through structured exercise or casual activities like walking, biking, or dancing, is a cornerstone of a...
172
Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the...
639